Understanding heterogeneity of treatment effect in prostate cancer

Current Opinion in Oncology

Volumn 27, Issue 3, 2015, Pages 209-216

  Aly, Abdalla ^a   Mullins, C Daniel ^a   Hussain, Arif ^b,c  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c BALTIMORE VA MEDICAL CENTER   (United States)

Author keywords

androgen deprivation therapy; Gleason score; heterogeneity of treatment effect; prostate cancer; survival

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; PROSTATE SPECIFIC ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DRUG EFFICACY; GLEASON SCORE; HUMAN; ONCOLOGIST; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; BLOOD; CANCER GRADING; DISEASE COURSE; GENETIC HETEROGENEITY; GENETICS; MALE; OBSERVATIONAL STUDY; PATHOLOGY; PREDICTIVE VALUE; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TUMOR INVASION;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE PROGRESSION; GENETIC HETEROGENEITY; HUMANS; MALE; NEOPLASM GRADING; NEOPLASM INVASIVENESS; OBSERVATIONAL STUDIES AS TOPIC; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84928476450     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000172     Document Type: Review

References (29)

1. Mullins CD, Montgomery R, Tunis S. Uncertainty in assessing value of oncology treatments. Oncologist 2010; 15 (Suppl 1):58-64.
2. Grivas PD, Robins DM, Hussain M. Predicting response to hormonal therapy and survival in men with hormone sensitive metastatic prostate cancer. Crit Rev Oncol Hematol 2013; 85:82-93.
3. Lazar AA, Cole BF, Bonetti M, Gelber RD. Evaluation of treatmenteffect heterogeneity using biomarkers measured on a continuous scale: subpopulation treatment effect pattern plot. J Clin Oncol 2010; 28:4539-4544.
4. Mitikiri ND, Reese ES, Hussain A, et al. The emerging relevance of heterogeneity of treatment effect in clinical care: a study using stage IV prostate cancer as a model. J Comp Eff Res 2013; 2:605-618.
5. Kravitz RL, Duan N, Braslow J. Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. Milbank Q 2004; 82:661-687.
6. Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014; 65:467-479.
7. Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgensensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007; 25:1596-1605.
8. Mohler J, Bahnson RR, Boston B, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2010; 8:162-200.
9. Egevad L, Granfors T, Karlberg L, et al. Prognostic value of the Gleason score in prostate cancer. BJU Int 2002; 89:538-542.
10. Willke RJ, Zheng Z, Subedi P, et al. From concepts, theory, and evidence of heterogeneity of treatment effects to methodological approaches: a primer. BMC Med Res Methodol 2012; 12:185-2288-12-185.
11. Little RJ, Rubin DB. Causal effects in clinical and epidemiological studies via potential outcomes: concepts and analytical approaches. Annu Rev Public Health 2000; 21:121-145.
12. Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med 2006; 25:127-141.
13. Royston P, Sauerbrei W. A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials. Stat Med 2004; 23:2509-2525.
14. Royston P, Sauerbrei W. Interactions between treatment and continuous covariates: a step toward individualizing therapy. J Clin Oncol 2008; 26:1397-1399.
15. Benaim EA, Pace CM, Roehrborn CG. Gleason score predicts androgen independent progression after androgen deprivation therapy. Eur Urol 2002; 42:12-17.
16. Oefelein MG, Ricchiuti VS, Conrad PW, et al. Clinical predictors of androgenindependent prostate cancer and survival in the prostate-specific antigen era. Urology 2002; 60:120-124.
17. Figg WD, Franks ME, Venzon D, et al. Gleason score and pretreatment prostate-specific antigen in survival among patients with stage D2 prostate cancer. World J Urol 2004; 22:425-430.
18. Ross RW, Xie W, Regan MM, et al. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Cancer 2008; 112:1247-1253.
19. Divrik RT, Turkeri L, Sahin AF, et al. Prediction of response to androgen deprivation therapy and castration resistance in primary metastatic prostate cancer. Urol Int 2012; 88:25-33.
20. Tomioka A, Tanaka N, Yoshikawa M, et al. Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer. BMC Urol 2014; 14:33-2490-14-33.
21. Byar DP, Green SB. The choice of treatment for cancer patients based on covariate information. Bull Cancer 1980; 67:477-490.
22. Glass TR, Tangen CM, Crawford ED, Thompson I. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol 2003; 169:164-169.
23. Yossepowitch O, Bianco FJ Jr, Eggener SE, et al. The natural history of noncastrate metastatic prostate cancer after radical prostatectomy. Eur Urol 2007; 51:940-947.
24. Sharifi N, Dahut WL, Steinberg SM, et al. A retrospective study of the time to clinical endpoints for advanced prostate cancer. BJU Int 2005; 96:985-989.
25. Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 2009; 6:76-85.
26. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321:419-424.
27. Denis LJ, Keuppens F, Smith PH, et al. Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and theEORTCData Center. Eur Urol 1998; 33:144-151.
28. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339:1036-1042.
29. Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr 1988; 7:165-170.